Eosinophilic otitis media; state-of-the-art diagnosis and treatment.

Biologics Bronchial asthma Chronic eosinophilic rhinosinusitis Diagnostic criteria Eosinophilic otitis media Type 2 inflammation

Journal

Auris, nasus, larynx
ISSN: 1879-1476
Titre abrégé: Auris Nasus Larynx
Pays: Netherlands
ID NLM: 7708170

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 29 10 2022
revised: 11 11 2022
accepted: 21 11 2022
medline: 19 6 2023
pubmed: 18 12 2022
entrez: 17 12 2022
Statut: ppublish

Résumé

Eosinophilic otitis media (EOM) is an intractable otitis media with highly viscous middle ear effusion and is usually associated with bronchial asthma. Since the diagnostic criteria of EOM were established in 2011, the concept of EOM has been known worldwide. EOM is caused by Type 2 inflammation in the respiratory tract, similar to bronchial asthma and eosinophilic rhinosinusitis. With the appreciation of Type 2 inflammatory diseases, EOM is no longer considered to be a rare disease and should be specifically treated to improve quality of life. The diagnosis of EOM needs to be reconsidered because many reports have described varying pathogenesis and mechanisms of rare middle ear conditions. Systemic and topical administration of corticosteroids is presently the most effective treatment to control EOM. However, EOM treatments are developing because various biologics have been used to treat patients with bronchial asthma with and without eosinophilic rhinosinusitis and EOM. Surgical intervention is also no longer contraindicated with the use of biologics. These advances represent the beginning of a new stage of basic and clinical research for EOM. This review focuses on the diagnosis and treatment of EOM based on the most recent advances regarding EOM.

Identifiants

pubmed: 36528403
pii: S0385-8146(22)00225-5
doi: 10.1016/j.anl.2022.11.004
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

479-489

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Disclosure Statement We have no conflicts of interest to disclose in connection with this review.

Auteurs

Yukiko Iino (Y)

Department of Otolaryngology / Deafness and Middle Ear Surgicenter, Tokyo Kita Medical Center, 4-17-56 Akabanedai, Kita-ku, Tokyo 115-0053, Japan; Department of Otolaryngology-Head and Neck Surgery, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-0834, Japan. Electronic address: yiino@jichi.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH